Benzinga | Jun 28, 2021 07:40AM EDT

Goldman Sachs Maintains Buy on Intellia Therapeutics, Raises Price Target to $163

Goldman Sachs analyst Salveen Richter maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $115 to $163.